▟ Vinebot intrinsic value, daily

← back

STE Steris

healthcare · valued with opus medium conviction · deep-dived 2026-11-13

HOLD
Intrinsic value$134.19
Price (at call)$253.44
Margin of safety -47.1%
vs market (rating basis) -11.6%

Quality sterilization franchise with better reinvestment than reported, but $253 still prices in near-perfect execution.

The story

Steris is a sterilization and infection-prevention toll-collector. Roughly 70% of revenue is recurring consumables, services and contract sterilization (AST), tied to procedure volumes and device makers' regulatory requirements. Switching costs and validation lock-in make it a durable, mature compounder. Margins are recovering as Cantel integration costs roll off and AST capacity investments start to pay off.

TTM GAAP margin rose to 19.2% from 18.7%, so the target moves up modestly to 22%, consistent with adjusted margins and fading amortization. Sales-to-capital rises from 1.0 to 1.3, a material move: capex ($0.35B) now runs below D&A ($0.49B), and the reported 0.68 is deflated by Cantel goodwill, which overstates the capital needed for incremental growth. The horizon extends from 8 to 10 years to reflect the recurring, regulation-locked consumables base. At $253 the gap to my previous value was nearing 2x, so this re-check against the market is warranted.

Value drivers

Revenue growth (Y1)7.0%
Terminal growth3.0%
Forecast horizon10y
Target operating margin22.0%
Years to target margin4
Sales-to-capital1.30
Beta0.88
Failure probability1.0%
Cost of capital (WACC)8.8%
Terminal WACC9.3%

Valuation bridge

PV of explicit FCFF6.55B
PV of terminal value8.12B
Equity value13.03B
÷ shares → per share$134.19

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 6.60B 7.0% 19.9% 982.37M 332.01M 650.36M 597.96M
2 7.03B 6.6% 20.6% 1.08B 332.70M 751.62M 635.38M
3 7.46B 6.1% 21.3% 1.19B 330.47M 859.94M 668.37M
4 7.88B 5.7% 22.0% 1.30B 325.16M 974.80M 696.60M
5 8.29B 5.2% 22.0% 1.37B 316.64M 1.05B 690.67M
6 8.69B 4.8% 22.0% 1.43B 304.82M 1.13B 681.64M
7 9.07B 4.3% 22.0% 1.50B 289.67M 1.21B 669.62M
8 9.42B 3.9% 22.0% 1.55B 271.23M 1.28B 654.78M
9 9.74B 3.4% 22.0% 1.61B 249.57M 1.36B 637.31M
10 10.04B 3.0% 22.0% 1.66B 224.86M 1.43B 617.44M

Key risks

  • Hospital capital-equipment budget cuts or a slowdown in procedure volumes
  • Regulatory pressure on ethylene oxide (EtO) sterilization raising AST compliance costs or forcing plant changes
  • Multiple compression if growth falls back to mid-single digits while the stock trades near 30x earnings

Catalysts

  • AST capacity additions (X-ray/E-beam) converting to high-margin volume
  • Continued margin expansion and deleveraging as amortization fades and integration finishes

History

DatePriceIntrinsicMoSRating
2026-11-13$253.44 $134.19 -47.1% HOLD
2026-09-24$209.98 $113.20 -46.1% HOLD
2026-08-05$232.85 $106.68 -54.2% HOLD
2026-06-23$203.21 $115.65 -43.1% HOLD